insulin-secreting adipose-derived mesenchymal stem cells + hematopoietic stem cells

This investigational combination cell therapy, developed by the Institute of Kidney Diseases and Research Centre (IKDRC) and the Dr. H.L. Trivedi Institute of Transplantation Sciences, consists of insulin-secreting cells differentiated in vitro from adipose-derived mesenchymal stem cells (IS-AD-MSCs) and donor-derived hematopoietic stem cells (HSCs). The therapy is primarily investigated for patients with Type 1 Diabetes Mellitus (T1DM), particularly those with end-stage renal disease (ESRD) requiring kidney transplantation. The IS-AD-MSCs are differentiated to express pancreatic markers such as Pax-6, Isl-1, and pdx-1 to replace lost beta-cell function and regulate blood glucose. The co-infusion of HSCs is designed to induce mixed chimerism, re-educating the recipient's immune system to recognize the transplanted cells and kidney as 'self,' thereby preventing autoimmune destruction and transplant rejection while minimizing or eliminating the need for long-term immunosuppression. The treatment is typically administered via a multi-route protocol involving the portal circulation, thymic circulation, and subcutaneous tissue.

Other names

adipose-derived insulin-producing cells + hematopoietic stem cellsIKDRC-ITS stem cell therapyinsulin-producing cells differentiated from adipose tissue-derived mesenchymal stem cells + bone marrow-derived hematopoietic stem cells